Cargando…
Can a Single Measurement of Apixaban Levels Identify Patients at Risk of Overexposure? A Prospective Cohort Study
Background Patients with atrial fibrillation (AF) are frequently treated with apixaban 2.5-mg twice daily (BID) off-label, presumably to reduce the bleeding risk. However, this approach has the potential to increase the risk of ischemic stroke. If a single measurement could reliably identify patien...
Autores principales: | de Vries, Tim A.C., Hirsh, Jack, Bhagirath, Vinai C., Ginsberg, Jeffrey S., Pisters, Ron, Hemels, Martin E.W., de Groot, Joris R., Eikelboom, John W., Chan, Noel C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786560/ https://www.ncbi.nlm.nih.gov/pubmed/35088021 http://dx.doi.org/10.1055/s-0041-1740492 |
Ejemplares similares
-
Plasma Rivaroxaban Level to Identify Patients at Risk of Drug Overexposure: Is a Single Measurement of Drug Level Reliable?
por: Shyamkumar, Krishnan, et al.
Publicado: (2021) -
Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial
por: Bhagirath, Vinai C., et al.
Publicado: (2017) -
Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism
por: Chan, Noel C, et al.
Publicado: (2015) -
Northern overexposure.
por: Tenenbaum, D J
Publicado: (1998) -
Prevention of Venous Thromboembolism in 2020 and Beyond
por: Nicholson, Matthew, et al.
Publicado: (2020)